专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20070212743A1 Assays for Determining Anticoagulant Cofactor Activity 审中-公开
标题翻译：测定抗凝血因子活性的方法
公开(公告)号：US20070212743A1
公开(公告)日：2007-09-13
申请号：US11560502
申请日：2006-11-16
申请人： Björn Dahlbäck
发明人： Björn Dahlbäck
IPC分类号： C12Q1/56
CPC分类号： C12Q1/56 , A61K38/36 , C07K14/745 , C07K16/36 , G01N33/86 , G01N2333/96461 , G01N2333/96463
摘要： Methods are disclosed for determining, in a sample derived from a human, the functional activity of a component of the human blood coagulation system, which activity can be correlated to conversion of a substrate specific for activated Protein C (APC), by measuring in an assay medium containing the sample and a substrate for APC, the conversion of the substrate by APC and correlating the conversion to the functional activity of the component. When the component is anticoagulant Factor V, at least one of exogenous APC, Protein S or an inhibitor of Protein S activity is added to the medium. When the component is Protein C, APC, or Protein S, exogenous anticoagulant Factor V or an inhibitor of anticoagulant activity of Factor V is added to the medium. Methods are also disclosed for diagnosing a blood coagulation/anticoagulation disorder or for determining a predisposition thereto in a human by determining anticoagulant Factor V activity in an assay medium containing a sample derived from the human.
摘要翻译：公开了用于在来自人类的样品中测定人类血液凝固系统的组分的功能活性的方法，该活性可以与活化蛋白C（APC）特异性底物的转化相关，通过在含有样品和APC底物的测定培养基，通过APC转化底物并将转化与组分的功能活性相关联。当组分是抗凝血因子V时，将外源APC，蛋白S或蛋白S活性抑制剂中的至少一种加入到培养基中。当组分为蛋白C，APC或蛋白S时，将外源抗凝血因子V或因子V的抗凝血活性抑制剂加入到培养基中。还公开了通过在含有源自人的样品的测定培养基中测定抗凝血因子V活性来诊断血液凝固/抗凝障碍或用于确定人类易感性的方法。

62. 发明申请

US20060275277A1 Use of coagulation proteins to lyse clots 审中-公开
标题翻译：使用凝血蛋白溶解凝块
公开(公告)号：US20060275277A1
公开(公告)日：2006-12-07
申请号：US10551565
申请日：2004-04-02
申请人： Edward Pryzdial
发明人： Edward Pryzdial
IPC分类号： A61K38/54 , C12Q1/37 , A61K31/727
CPC分类号： G01N33/86 , A61K31/727 , A61K38/4846 , A61K38/49 , A61K38/58 , A61K45/06 , C12Q1/37 , G01N33/6893 , G01N2333/96463 , G01N2800/224 , A61K2300/00
摘要： The present invention relates to the use of coagulation proteins for the lysis of blood clots. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein comprising a basic C-terminal amino acid, wherein the coagulation protein may be a derivative of Factor X or Factor V or a combination thereof. Pharmaceutical compositions for the treatment and prophylaxis of blood clots are also provided, wherein, the methods and products of the present invention advantageously accelerate clot dissolution while potentially minimizing the adverse side-effects, such as hemorrhaging, seen with other clot dissolving agents. The present invention also provides a method for detecting a fibrinolytic potential in a subject.
摘要翻译：本发明涉及凝血蛋白用于血栓溶解的用途。更具体地，本发明提供了一种通过施用包含碱性C末端氨基酸的至少一种凝血蛋白来加速血块溶解的方法，其中凝血蛋白可以是因子X或因子Ⅴ的衍生物或其组合。还提供了用于治疗和预防血凝块的药物组合物，其中，本发明的方法和产品有利地加速凝块溶解，同时潜在地最小化其他凝块溶解剂所见的不良副作用，例如出血。本发明还提供了一种用于检测受试者中的纤维蛋白溶解电位的方法。

63. 发明申请

US20060040323A1 Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis 有权
标题翻译：用于肝素诱导的血小板减少/血栓形成的诊断和治疗的组合物和方法
公开(公告)号：US20060040323A1
公开(公告)日：2006-02-23
申请号：US11195095
申请日：2005-08-02
申请人： Gowthami Arepally , Walter Kisiel , Keiko Kamei , Shintaro Kamei
发明人： Gowthami Arepally , Walter Kisiel , Keiko Kamei , Shintaro Kamei
IPC分类号： G01N33/53 , C07K16/44 , C07K16/22
CPC分类号： C07K16/24 , C07K16/18 , C07K2317/32 , C07K2317/75 , G01N33/86 , G01N2333/96463 , G01N2400/40 , Y10S435/975 , Y10S530/866
摘要： The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.
摘要翻译：本发明包括组合物，试剂盒和方法，其包含与哺乳动物参与肝素诱导的血小板减少症/血栓形成（HIT / HITT）发病机理的多克隆抗体共享关键功能特性的单克隆抗体。本发明的单克隆抗体相对于抗体与单独的PF4或肝素的结合优先与PF4 /肝素复合物结合。本发明的单克隆抗体也与除了肝素之外的其它糖胺聚糖的复合物中的PF4特异性结合，并且还激活血小板。本发明的单克隆抗体可用于哺乳动物诊断和治疗HIT / HITT的方法。还包括本发明的单克隆抗体的人源化版本，以及本发明的单克隆抗体的人源化方法。

64. 发明授权

US06867045B1 Method for diagnosis of thrombotic disorders 失效
标题翻译：诊断血栓形成障碍的方法
公开(公告)号：US06867045B1
公开(公告)日：2005-03-15
申请号：US09606779
申请日：2000-06-28
申请人： John H. Griffin , Samuel I. Rapaport , Dzung T. Le
发明人： John H. Griffin , Samuel I. Rapaport , Dzung T. Le
IPC分类号： C12Q1/56 , G01N33/86
CPC分类号： G01N33/86 , G01N2333/745 , G01N2333/96444 , G01N2333/96461 , G01N2333/96463 , G01N2400/40 , G01N2405/04
摘要： The present invention provides an in vitro method useful for the diagnosis of a thrombotic disorder in a subject, having or at risk of having the disorder. Specifically, the disorder exemplified herein is associated with APC resistant Factor V and Va. The clotting time of a test sample is analyzed in the presence and absence of APC and compared with a standard reference sample in order to diagnose the subject.
摘要翻译：本发明提供了一种用于诊断受试者的血栓形成障碍的体外方法，所述血栓形成障碍具有或具有疾病风险。具体来说，本文所示的病症与APC抗性因子V和Va相关。在APC存在和不存在的情况下分析测试样品的凝血时间，并与标准参考样品进行比较以诊断受试者。

65. 发明授权

US6114136A Compositions used as a pathological control in a method for the detection of resistance to activated protein C, method for the preparation of these compositions and use in said detection method 有权
标题翻译：用于检测活化蛋白C抗性的方法中的病理学控制的组合物，用于制备这些组合物的方法和用于所述检测方法
公开(公告)号：US6114136A
公开(公告)日：2000-09-05
申请号：US316005
申请日：1999-05-21
申请人： Patrick Van Dreden , Jean-Luc Martinoli
发明人： Patrick Van Dreden , Jean-Luc Martinoli
IPC分类号： G01N33/86 , G01N33/96 , C12Q1/56 , C12Q1/00
CPC分类号： G01N33/86 , G01N33/96 , G01N2333/745 , G01N2333/96463 , G01N2496/05 , Y10S435/967 , Y10S435/975
摘要： The invention relates to the use of a serum rich in factor Va for the preparation of compositions useful as pathological controls or calibrants in methods for analyzing resistance to activated protein C (APC), as well as said compositions, the method for their preparation and a method for the detection of resistance to activated protein C.
摘要翻译：本发明涉及富含因子Va的血清在用于分析对活化蛋白C（APC）的抗性的方法中用作病理学对照或校准物的组合物的用途，以及所述组合物，其制备方法和检测抗活化蛋白C的方法

66. 发明授权

US6051434A Activated protein C resistance test 失效
标题翻译：活化蛋白C电阻测试
公开(公告)号：US6051434A
公开(公告)日：2000-04-18
申请号：US776897
申请日：1997-04-24
申请人： Thomas Exner
发明人： Thomas Exner
IPC分类号： G01N33/86
CPC分类号： G01N33/86 , G01N2333/4613 , G01N2333/4616 , G01N2333/96444 , G01N2333/96461 , G01N2333/96463 , Y10T436/25
摘要： The method for determining functional activity of protein C in a human plasma sample includes incubating the human plasma sample with exogenous reagents that activate factor V and a common pathway of the blood coagulation mechanism through factor X, with activated exogenous protein C and with components that are necessary for efficient clotting of the human plasma sample, or incubating the human plasma sample with exogenous reagents that induce the presence of thrombin in a factor V dependent manner, with activated exogenous protein C and with components that are necessary for efficient clotting of the human plasma sample; monitoring a reaction indicative of a potential rate of coagulation of the plasma sample and comparing the resulting potential rate of coagulation with an equivalent rate for normal patient, or comparing the resulting potential rate of coagulation with an equivalent rate determined for the plasma sample in the absence of activated exogenous protein C; and determining the functional activity of the free protein C from this comparison.
摘要翻译： PCT No.PCT / AU95 / 00474 Sec。 371日期1997年04月24日 102（e）日期1997年4月24日PCT提交1995年8月7日PCT公布。公开号WO96 / 04560 日期1996年2月15日人血浆样品中蛋白C的功能活性测定方法包括通过激活的外源蛋白C将人血浆样品与激活因子V的外源试剂和通过因子X的凝血机制的共同途径进行孵育以及用于有效凝固人血浆样品所必需的成分，或用活化的外源蛋白C以及有效成分所必需的成分，以以因子V依赖性方式诱导凝血酶存在的外源试剂孵育人血浆样品人血浆样品凝结; 监测指示血浆样品的潜在凝血速率的反应并将所得到的潜在凝血速率与正常患者的等效速率进行比较，或将所得到的潜在凝血速率与在不存在的血浆样品中测定的等效速率进行比较的活化外源蛋白C; 并从该比较中确定游离蛋白C的功能活性。

67. 发明授权

US5753510A Calibrator for use in test methods for detecting a defective coagulation factor V 失效
标题翻译：校准器用于检测有缺陷的凝血因子V的测试方法
公开(公告)号：US5753510A
公开(公告)日：1998-05-19
申请号：US551838
申请日：1995-11-07
申请人： Michael Kraus
发明人： Michael Kraus
IPC分类号： C12Q1/56 , G01N33/86 , G01N33/96
CPC分类号： G01N33/86 , C12Q1/56 , G01N33/96 , G01N2333/7456 , G01N2333/96461 , G01N2333/96463 , G01N2496/05 , Y10T436/10 , Y10T436/105831 , Y10T436/106664 , Y10T436/107497
摘要： The invention relates to a plasma which can be used as a calibrator in coagulation tests which detect the degradation of factor V by activated protein C, to the preparation of such a plasma and to its use.
摘要翻译：本发明涉及一种等离子体，其可以用作凝血试验中的校准器，其用于检测由活化蛋白C导致的因子V的降解，制备这种血浆及其用途。

68. 发明授权

US5705395A Method for diagnosis of thrombotic disorders 失效
公开(公告)号：US5705395A
公开(公告)日：1998-01-06
申请号：US339828
申请日：1994-11-14
申请人： John H. Griffin , Samuel I. Rapaport , Dzung T. Le
发明人： John H. Griffin , Samuel I. Rapaport , Dzung T. Le
IPC分类号： G01N33/86
CPC分类号： G01N33/86 , G01N2333/745 , G01N2333/96461 , G01N2333/96463 , G01N2400/40 , G01N2405/04 , Y10S435/81 , Y10S435/975
摘要： The present invention provides an in vitro method useful for the diagnosis of a thrombotic disorder in a subject, having or at risk of having the disorder. Specifically, the disorder exemplified herein is associated with APC resistant Factor V and Va. The clotting time of a test sample is analyzed in the presence and absence of APC and compared with a standard reference sample in order to diagnose the subject.

69. 发明公开

US20240151714A1 TARGET ANALYTE DETECTION METHOD BASED ON PROXIMITY PROTEOLYSIS REACTION 审中-公开
公开(公告)号：US20240151714A1
公开(公告)日：2024-05-09
申请号：US18281460
申请日：2022-03-14
申请人： AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
发明人： Tae Hyeon YOO , Hyeon Ji PARK
IPC分类号： G01N33/53 , G01N33/573 , G01N33/68 , G01N33/74 , G01N33/76
CPC分类号： G01N33/5308 , G01N33/573 , G01N33/6887 , G01N33/74 , G01N33/76 , G01N2333/4712 , G01N2333/59 , G01N2333/71 , G01N2333/96463
摘要： The present invention relates to a target analyte detection composition based on a proximity proteolysis reaction and a target analyte detection method using same. More specifically, the present invention relates to a method for detecting a target analyte, the method comprising a step in which when a first binder and a second binder bind to the target analyte, hybridization is made between ssDNA linked to the first binder and ssDNA linked to a protease and between ssDNA linked to the second binder and ssDNA linked to a zymogen, whereby a signal generated by a proximity proteolysis reaction between the protease and the zymogen is detected.

70. 发明授权

US10066224B2 Method for purifying and quantifying thrombin and its degradation polypeptides 有权
公开(公告)号：US10066224B2
公开(公告)日：2018-09-04
申请号：US15051821
申请日：2016-02-24
申请人： Omrix Biopharmaceuticals Ltd.
发明人： Tamar Auerbach-Nevo , Nadav Orr , Israel Nur
IPC分类号： C12Q1/56 , C12N9/74 , G01N33/49 , C07K14/745 , A61K38/00
CPC分类号： C12N9/6429 , A61K38/00 , C07K14/745 , C12Q1/56 , C12Y304/21005 , G01N33/491 , G01N2333/96463
摘要： Provided is a method for purifying α-thrombin and for quantifying α-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified α-thrombin. The method can also be used for purification and/or quantification of β-thrombin.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式